The EarlyVue VS30 uses automated early warning scoring (EWS) to collect the vital signs and calculate the alerts to allow clinicians to identify subtle signs of patient deterioration. The capabilities are designed to enable clinicians to facilitate communication between caregivers for timely intervention and patient care.
The FDA-cleared EarlyVue VS30 monitor is designed to allow clinicians to view vitals at the bedside or remotely through a data sharing feature that transmits information from monitor to monitor.
EarlyVue VS30 also captures patient data and securely transmits it into a hospital’s electronic medical records in an effort to reduce errors and support gap-free patient records and improve patient outcomes.
“With preventable patient adverse events and clinical workflow issues on the rise, it’s imperative that the healthcare industry looks for ways to alleviate these challenges,” business leader of Philips monitoring & analytics Peter Ziese said in a news release. “Integrated technology with smart algorithms, like EarlyVue VS30, can benefit both clinicians and patients by limiting transcription errors and providing early risk-based alerts for timely interventions – allowing clinicians to, confidently and proactively deliver care.”
Shares of PHG were down -0.8% at $44.05 per share in mid-afternoon trading today.